Board of Directors

Sujal Shah, Board of Director at Tvardi Therapeutics, Houston TX

Sujal Shah

Chairman of the Board
CEO, CymaBay Therapeutics

Sujal Shah has been President and Chief Executive Officer at CymaBay Therapeutics since 2017 stewarding the company through the NDA filing of its lead compound which ultimately led to the acquisition of CymaBay by Gilead for $4.3 Billion in 2024. Prior to 2017, he served as Chief Financial Officer taking CymaBay public in 2014. Before joining CymaBay in 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010, Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah received an MBA from Carnegie Mellon University Tepper School of Business and MS and BS degrees in Biomedical Engineering from Northwestern University.

CEO Imran Alibhai

Imran Alibhai, Ph.D.

Chief Executive Officer

Prior to becoming CEO of Tvardi, Imran Alibhai, Ph.D. was a Senior Vice President and Managing Director of DNAtrix, a clinical stage biotech company developing oncolytic viruses for cancer. Previously, Dr. Alibhai was an investment banker in PJ Solomon’s Healthcare Advisory Group, focused on M&A transactions in science-based markets including biopharmaceuticals, medical devices/diagnostics and life science tools. Formerly, he was the Senior Director at Alexandria Venture Investments, where he was responsible for investments in emerging companies and funds in the healthcare sector. He also directed investments for PIPE’s and long/short positions in MPM Capital’s BioEquities hedge fund. Dr. Alibhai began his career in early stage venture capital at the Accelerator Corp., where he was involved in every facet of company/project formation and management. He currently serves on the Scientific Advisory Board for NASA’s Translational Research Institute for Space Health. Dr. Alibhai holds a Ph.D. in Molecular Neuroscience from the University of Texas Southwestern Medical School and a BS in Biology from Duke University.

Wallace Hall, Board of Director at Tvardi Therapeutic, Houston TX

Wallace Hall

Founder & President, Wetland Partners, LP.

Mr. Hall is founder and president of Wetland Partners, LP., which is primarily engaged in wetland mitigation banking and oil & gas investments. Mr. Hall is also a co-founder of BioMatrix Partners, an investment partnership focused on public and private biotechnology companies, with an emphasis on early-stage opportunities enabled by synthetic biology. Mr. Hall has invested in a wide range of businesses for over 30 years, serving in a variety of leadership capacities. An active member of his community, Mr. Hall has served in multiple leaderships roles with St. Mark’s School of Texas, the Texas Higher Education Coordinating Board, and most recently, a six-year term with the University of Texas System Board of Regents. He is a graduate of the University of Texas at Austin with a Bachelor of Arts in Economics.

Jamie McNab, Board of Directors at Tvardi Therapeutics, Houston TX

Jamie McNab

Partner, Slate Path Capital

Jamie McNab is a partner at Slate Path Capital, an investment firm based in New York City. Before joining Slate Path when it was founded in 2012, Mr. McNab worked at Blue Ridge Capital. Previously, he worked at Sentinel Capital Partners, a private equity firm, where he focused on leveraged buyouts. Mr. McNab began his career at the boutique investment-banking firm Edgeview Partners, where he worked on corporate mergers and acquisitions. He serves on the board of the Tiger Foundation and is a member of the Leadership Council for the Mindich Child Health and Development Institute at Mount Sinai’s Icahn School of Medicine. Mr. McNab earned his MBA from the Stanford Graduate School of Business and a BA in history, magna cum laude, from Davidson College, where he was a member of Phi Beta Kappa.

Shaheen Wirk, M.D.

Founder and Chief Investment Officer,
Palkon Capital Management

Dr. Shaheen Wirk has 20+ years of investment experience in public and private life science companies. He is the founder and Chief Investment Officer of Palkon Capital Management, a healthcare-dedicated investment firm launched in partnership with Julian Robertson and Tiger Management. Formerly, Dr. Wirk was a senior analyst at Bridger Capital. He is the founder of the advisory firm Blue Continga and was an early employee at MercuryMD (acquired by the Thomson Corporation). Dr. Wirk completed research training programs in oncology and trauma surgery at the University of Texas MD Anderson Cancer Center, Rabin Medical Center through the National Institutes of Health Fogarty International Center, and Duke University Medical Center. Dr. Wirk earned his M.D., M.B.A., and B.S. degrees from Duke University.

Michael Wyzga

Michael Wyzga has spent 30+ years in leadership roles in the biopharma industry. He served as Chief Financial Officer at Genzyme, stewarding the company through a myriad of transactions ultimately culminating in the acquisition of Genzyme by Sanofi for $20 billion. He also served as President, Chief Executive Officer and board member at Radius Health, a publicly traded biopharmaceutical company targeting osteoporosis. Mr. Wyzga received an MBA from Providence College and a BS from Suffolk University.

Scroll to Top

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.